TDMS Study 05133-03 Pathology Tables
INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
ACETONITRILE
NTP Experiment-Test: 05133-03 Report: PEIRPT03
Study Type: CHRONIC Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:11:11
Facility: Battelle Northwest
Chemical CAS #: 75-05-8
Lock Date: 05/15/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05133-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:11:11
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 56 56 56 56
Scheduled Sacrifice 8 8 8 8
Early Deaths
Moribund Sacrifice 24 25 21 14
Accidently Killed 1
Natural Death 2 1 5
Survivors
Terminal Sacrifice 23 21 26 29
Animals Examined Microscopically 56 56 56 56
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (56) (56) (56) (55)
Mediastinum, Cyst 1 (2%)
Intestine Large, Colon (55) (55) (56) (53)
Inflammation, Suppurative 1 (2%)
Lumen, Parasite Metazoan 2 (4%) 1 (2%)
Intestine Large, Rectum (55) (56) (56) (53)
Ulcer 1 (2%)
Lumen, Parasite Metazoan 2 (4%) 6 (11%) 3 (6%)
Intestine Large, Cecum (55) (54) (55) (53)
Lumen, Parasite Metazoan 1 (2%) 2 (4%)
Intestine Small, Jejunum (55) (55) (56) (53)
Inflammation, Granulomatous 1 (2%)
Intestine Small, Ileum (55) (55) (54) (53)
Inflammation, Granulomatous 1 (2%)
Liver (56) (56) (56) (54)
Angiectasis 1 (2%)
Atrophy 1 (2%)
Basophilic Focus 40 (71%) 41 (73%) 38 (68%) 42 (78%)
Clear Cell Focus 2 (4%) 2 (4%) 1 (2%)
Degeneration, Cystic 1 (2%) 1 (2%)
Eosinophilic Focus 1 (2%)
Granuloma, Multifocal 4 (7%) 2 (4%) 3 (6%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%)
Hepatodiaphragmatic Nodule 7 (13%) 3 (5%) 8 (14%) 8 (15%)
Infarct 1 (2%)
Mixed Cell Focus 2 (4%)
Vacuolization Cytoplasmic 11 (20%) 14 (25%) 12 (21%) 20 (37%)
Bile Duct, Hyperplasia 2 (4%)
Hepatocyte, Degeneration, Cystic 1 (2%) 1 (2%) 3 (6%)
Hepatocyte, Hyperplasia 7 (13%) 9 (16%) 4 (7%) 10 (19%)
Hepatocyte, Necrosis 1 (2%) 3 (5%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05133-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:11:11
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Portal, Fibrosis 1 (2%)
Serosa, Cyst 1 (2%)
Serosa, Hemorrhage 1 (2%) 1 (2%)
Mesentery (10) (9) (8) (11)
Hemorrhage 1 (10%) 1 (11%) 2 (25%) 1 (9%)
Artery, Inflammation 1 (11%) 1 (13%)
Fat, Inflammation, Granulomatous 1 (10%) 6 (67%) 4 (50%) 7 (64%)
Fat, Necrosis 7 (70%) 2 (22%) 4 (50%) 9 (82%)
Pancreas (56) (56) (56) (54)
Acinus, Atrophy 15 (27%) 22 (39%) 29 (52%) 27 (50%)
Artery, Inflammation 1 (2%) 1 (2%)
Salivary Glands (56) (54) (56) (55)
Duct, Mineralization 1 (2%)
Stomach, Forestomach (56) (56) (55) (54)
Diverticulum 2 (4%)
Edema 2 (4%) 3 (5%) 5 (9%)
Hyperplasia, Basal Cell 1 (2%) 2 (4%)
Hyperplasia, Squamous 3 (5%) 6 (11%) 8 (15%) 7 (13%)
Inflammation, Suppurative 2 (4%) 5 (9%) 4 (7%) 3 (6%)
Necrosis 1 (2%)
Ulcer 2 (4%) 3 (5%) 5 (9%) 5 (9%)
Stomach, Glandular (55) (56) (56) (54)
Mineralization 1 (2%)
Necrosis 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (56) (56) (56) (55)
Aorta, Inflammation 1 (2%)
Aorta, Mineralization 1 (2%)
Heart (56) (56) (56) (55)
Cardiomyopathy 2 (4%) 2 (4%) 2 (4%) 2 (4%)
Thrombosis 1 (2%) 1 (2%) 1 (2%)
Endocardium, Hyperplasia 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (56) (56) (56) (54)
Hemorrhage 1 (2%) 1 (2%)
Hyperplasia 1 (2%) 2 (4%)
Mineralization 1 (2%)
Vacuolization Cytoplasmic 6 (11%) 11 (20%) 5 (9%) 8 (15%)
Adrenal Medulla (56) (55) (55) (55)
Angiectasis 1 (2%)
Hyperplasia 5 (9%) 6 (11%) 3 (5%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05133-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:11:11
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Parathyroid Gland (52) (52) (51) (52)
Hyperplasia 3 (6%) 1 (2%)
Pituitary Gland (56) (56) (55) (53)
Cyst 13 (23%) 17 (30%) 14 (25%) 15 (28%)
Pars Distalis, Cyst 1 (2%) 1 (2%) 1 (2%)
Pars Distalis, Hemorrhage 1 (2%)
Pars Distalis, Hyperplasia 9 (16%) 5 (9%) 3 (5%) 3 (6%)
Thyroid Gland (56) (56) (56) (54)
Dilatation 1 (2%)
Ultimobranchial Cyst 1 (2%)
C-Cell, Hyperplasia 26 (46%) 39 (70%) 36 (64%) 39 (72%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (54) (50) (55) (53)
Ectasia 11 (20%) 4 (8%) 10 (18%) 14 (26%)
Hyperplasia 2 (4%) 4 (8%) 4 (7%) 3 (6%)
Inflammation, Suppurative 4 (7%) 3 (6%) 2 (4%) 6 (11%)
Ovary (56) (56) (56) (55)
Cyst 4 (7%) 3 (5%) 2 (4%) 5 (9%)
Inflammation, Granulomatous 1 (2%)
Uterus (56) (56) (56) (55)
Hemorrhage 1 (2%)
Thrombosis 1 (2%)
Cervix, Endometrium, Hyperplasia 1 (2%) 1 (2%)
Endometrium, Hyperplasia 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (56) (56) (56) (54)
Hyperplasia, Re Cell 1 (2%) 3 (5%) 2 (4%) 1 (2%)
Myelofibrosis 2 (4%)
Lymph Node (7) (6) (9) (8)
Axillary, Hyperplasia, Lymphoid 1 (11%)
Iliac, Pigmentation 1 (11%)
Lumbar, Pigmentation 1 (14%)
Pancreatic, Hemorrhage 1 (17%)
Pancreatic, Pigmentation 1 (11%)
Renal, Hemorrhage 1 (17%) 1 (11%)
Lymph Node, Bronchial (49) (44) (45) (48)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05133-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:11:11
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Hemorrhage 4 (8%) 1 (2%) 2 (4%)
Inflammation, Suppurative 1 (2%)
Lymph Node, Mandibular (54) (54) (52) (49)
Hemorrhage 1 (2%)
Hyperplasia, Lymphoid 2 (4%) 1 (2%) 4 (8%)
Lymph Node, Mesenteric (54) (55) (55) (55)
Hemorrhage 3 (5%) 2 (4%)
Hyperplasia, Lymphoid 2 (4%) 1 (2%)
Inflammation, Granulomatous 1 (2%)
Lymph Node, Mediastinal (56) (53) (53) (54)
Hemorrhage 11 (20%) 7 (13%) 3 (6%) 11 (20%)
Hyperplasia, Lymphoid 1 (2%)
Pigmentation 1 (2%)
Spleen (56) (56) (56) (53)
Developmental Malformation 1 (2%)
Fibrosis 1 (2%) 2 (4%) 1 (2%) 3 (6%)
Hematopoietic Cell Proliferation 1 (2%)
Hemorrhage 1 (2%) 2 (4%)
Hyperplasia, Re Cell 2 (4%) 3 (5%) 1 (2%)
Necrosis 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Thymus (56) (56) (55) (55)
Hemorrhage 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (56) (56) (56) (55)
Galactocele 2 (4%) 2 (4%)
Epithelium, Hyperplasia 1 (2%)
Skin (56) (56) (56) (56)
Acanthosis 1 (2%) 1 (2%)
Inflammation, Granulomatous 2 (4%) 1 (2%)
Inflammation, Suppurative 1 (2%) 2 (4%)
Ulcer 2 (4%) 1 (2%) 2 (4%)
Subcutaneous Tissue, Hemorrhage 1 (2%)
Subcutaneous Tissue, Necrosis 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (55) (56) (56) (55)
Fibrosis 1 (2%)
Periosteum, Cranium, Hemorrhage 1 (2%)
Vertebra, Fracture 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05133-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:11:11
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (56) (56) (56) (55)
Hemorrhage 4 (7%) 5 (9%) 8 (14%) 2 (4%)
Hydrocephalus 4 (7%) 6 (11%) 3 (5%) 5 (9%)
Necrosis 1 (2%)
Spinal Cord (1)
Hemorrhage 1 (100%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (55) (56) (56) (54)
Foreign Body 8 (15%) 2 (4%) 4 (7%) 4 (7%)
Hyperplasia 5 (9%) 1 (2%) 3 (5%) 4 (7%)
Inflammation, Suppurative 5 (9%) 6 (11%) 3 (6%)
Metaplasia, Squamous 7 (13%) 5 (9%) 7 (13%) 3 (6%)
Mineralization 1 (2%)
Lung (56) (56) (56) (54)
Hemorrhage 43 (77%) 37 (66%) 40 (71%) 38 (70%)
Infiltration Cellular, Histiocyte 11 (20%) 17 (30%) 17 (30%) 13 (24%)
Metaplasia, Osseous 1 (2%)
Alveolar Epithelium, Hyperplasia 6 (11%) 5 (9%) 2 (4%) 1 (2%)
Alveolus, Fibrosis 2 (4%) 1 (2%) 1 (2%)
Alveolus, Inflammation, Chronic 3 (5%) 1 (2%) 1 (2%)
Alveolus, Inflammation, Suppurative 2 (4%)
Pleura, Fibrosis 3 (5%) 2 (4%) 2 (4%) 1 (2%)
Nose (55) (55) (56) (54)
Foreign Body 2 (4%) 5 (9%) 1 (2%) 3 (6%)
Hemorrhage 1 (2%) 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%) 2 (4%)
Inflammation, Suppurative 1 (2%) 2 (4%) 3 (5%) 2 (4%)
Goblet Cell, Respiratory Epithelium,
Hypertrophy 3 (5%) 2 (4%) 2 (4%) 4 (7%)
Nasolacrimal Duct, Inflammation, Suppurative 3 (5%) 2 (4%)
Olfactory Epithelium, Metaplasia 1 (2%)
Respiratory Epithelium, Hyperplasia 2 (4%) 2 (4%) 2 (4%) 1 (2%)
Respiratory Epithelium, Metaplasia, Squamous 1 (2%) 1 (2%)
Trachea (56) (56) (56) (53)
Epithelium, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (4) (2) (4) (4)
Cataract 1 (25%) 2 (50%) 1 (25%)
Hemorrhage 2 (50%) 1 (50%) 2 (50%) 1 (25%)
Retina, Atrophy 1 (25%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05133-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:11:11
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (56) (56) (56) (54)
Infarct 1 (2%)
Nephropathy, Chronic 40 (71%) 38 (68%) 38 (68%) 40 (74%)
Cortex, Necrosis 5 (9%) 2 (4%) 5 (9%) 5 (9%)
Pelvis, Transitional Epithelium, Hyperplasia 1 (2%)
Renal Tubule, Inflammation, Suppurative 1 (2%)
Renal Tubule, Mineralization 44 (79%) 42 (75%) 48 (86%) 41 (76%)
Renal Tubule, Pigmentation, Hemosiderin 1 (2%)
Urinary Bladder (56) (56) (55) (53)
Transitional Epithelium, Hyperplasia 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 05133-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:11:11
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 56 56 56 56
Scheduled Sacrifice 8 8 8 8
Early Deaths
Moribund Sacrifice 36 26 35 26
Natural Death 1 8 4 5
Survivors
Terminal Sacrifice 11 13 9 17
Other 1
Animals Examined Microscopically 56 56 56 56
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (56) (50) (54) (53)
Lumen, Parasite Metazoan 4 (7%) 2 (4%) 4 (7%) 1 (2%)
Intestine Large, Rectum (55) (52) (55) (54)
Lumen, Parasite Metazoan 4 (7%) 4 (8%) 6 (11%) 5 (9%)
Intestine Large, Cecum (55) (51) (54) (52)
Lumen, Parasite Metazoan 4 (7%) 3 (6%) 1 (2%)
Intestine Small, Duodenum (55) (53) (56) (55)
Diverticulum 1 (2%)
Intestine Small, Jejunum (55) (50) (54) (52)
Parasite Metazoan 1 (2%) 1 (2%)
Liver (56) (55) (56) (56)
Angiectasis 1 (2%) 1 (2%)
Basophilic Focus 21 (38%) 28 (51%) 32 (57%) 38 (68%)
Clear Cell Focus 6 (11%) 1 (2%) 2 (4%) 7 (13%)
Degeneration, Cystic 16 (29%) 17 (31%) 8 (14%) 4 (7%)
Eosinophilic Focus 3 (5%) 7 (13%) 5 (9%) 10 (18%)
Granuloma, Multifocal 1 (2%)
Hematopoietic Cell Proliferation 2 (4%)
Hepatodiaphragmatic Nodule 2 (4%) 4 (7%) 5 (9%) 3 (5%)
Inflammation, Chronic 1 (2%)
Mixed Cell Focus 1 (2%) 1 (2%) 1 (2%) 5 (9%)
Pigmentation, Hemosiderin 1 (2%)
Thrombosis 2 (4%)
Vacuolization Cytoplasmic 11 (20%) 10 (18%) 12 (21%) 5 (9%)
Bile Duct, Hyperplasia 2 (4%) 2 (4%) 3 (5%)
Hepatocyte, Necrosis 7 (13%) 8 (15%) 1 (2%) 3 (5%)
Portal, Fibrosis 1 (2%)
Mesentery (10) (9) (9) (12)
Hemorrhage 3 (30%) 1 (11%) 4 (33%)
Fat, Inflammation, Granulomatous 1 (10%) 1 (11%) 3 (33%) 2 (17%)
Fat, Necrosis 7 (70%) 7 (78%) 1 (11%) 8 (67%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 05133-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:11:11
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Pancreas (56) (55) (56) (56)
Hemorrhage 2 (4%)
Acinus, Atrophy 24 (43%) 35 (64%) 29 (52%) 31 (55%)
Artery, Inflammation 1 (2%) 2 (4%)
Duct, Cyst 1 (2%) 1 (2%)
Duct, Hyperplasia 1 (2%)
Stomach, Forestomach (56) (55) (56) (55)
Acanthosis 4 (7%) 4 (7%) 10 (18%) 4 (7%)
Diverticulum 2 (4%) 2 (4%)
Edema 1 (2%) 3 (5%) 1 (2%)
Hyperkeratosis 2 (4%)
Inflammation, Suppurative 5 (9%) 4 (7%) 7 (13%) 1 (2%)
Mineralization 1 (2%) 1 (2%)
Necrosis 1 (2%)
Ulcer 4 (7%) 3 (5%) 7 (13%) 3 (5%)
Stomach, Glandular (56) (54) (56) (55)
Hemorrhage 1 (2%)
Inflammation, Suppurative 1 (2%)
Mineralization 1 (2%) 1 (2%) 1 (2%)
Necrosis 1 (2%) 1 (2%)
Ulcer 1 (2%) 1 (2%)
Tongue (2) (1)
Epithelium, Hyperplasia 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (56) (54) (56) (56)
Mineralization 1 (2%)
Aorta, Inflammation 1 (2%) 1 (2%)
Aorta, Mineralization 2 (4%) 1 (2%)
Heart (56) (55) (56) (56)
Cardiomyopathy 14 (25%) 11 (20%) 12 (21%) 11 (20%)
Atrium, Thrombosis 8 (14%) 3 (5%) 3 (5%) 1 (2%)
Myocardium, Mineralization 1 (2%) 1 (2%)
Myocardium, Necrosis 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (56) (55) (56) (56)
Hemorrhage 1 (2%) 2 (4%)
Hyperplasia 1 (2%)
Vacuolization Cytoplasmic 7 (13%) 8 (15%) 10 (18%) 7 (13%)
Adrenal Medulla (56) (53) (53) (56)
Hyperplasia 20 (36%) 16 (30%) 21 (40%) 16 (29%)
Islets, Pancreatic (56) (55) (56) (56)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 05133-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:11:11
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Hyperplasia 1 (2%) 2 (4%)
Parathyroid Gland (54) (49) (54) (49)
Hyperplasia 2 (4%) 5 (10%) 4 (7%) 2 (4%)
Pituitary Gland (56) (53) (56) (54)
Cyst 3 (5%) 7 (13%) 8 (14%) 4 (7%)
Hemorrhage 1 (2%) 2 (4%) 1 (2%)
Pars Distalis, Hemorrhage 1 (2%)
Pars Distalis, Hyperplasia 8 (14%) 9 (17%) 9 (16%) 10 (19%)
Pars Intermedia, Hyperplasia 1 (2%)
Thyroid Gland (56) (55) (56) (56)
Ultimobranchial Cyst 2 (4%)
C-Cell, Hyperplasia 10 (18%) 10 (18%) 9 (16%) 12 (21%)
Follicle, Dilatation 1 (2%)
Follicular Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (56) (55) (56) (56)
Inflammation, Suppurative 1 (2%)
Preputial Gland (55) (55) (55) (56)
Ectasia 22 (40%) 16 (29%) 25 (45%) 16 (29%)
Granuloma 1 (2%)
Hyperplasia 1 (2%) 2 (4%) 2 (4%) 3 (5%)
Inflammation, Chronic 1 (2%) 4 (7%)
Inflammation, Suppurative 7 (13%) 7 (13%) 6 (11%) 8 (14%)
Prostate (56) (55) (56) (56)
Cyst 1 (2%)
Inflammation, Suppurative 9 (16%) 10 (18%) 9 (16%) 12 (21%)
Epithelium, Hyperplasia 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Seminal Vesicle (56) (54) (56) (56)
Hyperplasia 1 (2%) 1 (2%) 1 (2%)
Inflammation, Suppurative 1 (2%) 2 (4%) 2 (4%)
Testes (56) (55) (56) (56)
Hemorrhage 1 (2%) 1 (2%)
Inflammation, Suppurative 1 (2%)
Necrosis 1 (2%)
Germinal Epithelium, Atrophy 10 (18%) 13 (24%) 9 (16%) 9 (16%)
Interstitial Cell, Hyperplasia 21 (38%) 19 (35%) 21 (38%) 9 (16%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 05133-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:11:11
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (56) (55) (56) (56)
Hyperplasia, Re Cell 7 (13%) 1 (2%)
Myelofibrosis 2 (4%)
Lymph Node (12) (8) (15) (13)
Inflammation, Granulomatous 1 (8%)
Iliac, Pigmentation 1 (8%)
Lumbar, Pigmentation 1 (8%) 1 (13%) 2 (13%) 1 (8%)
Pancreatic, Hyperplasia, Lymphoid 1 (8%)
Renal, Ectasia 1 (13%)
Renal, Hemorrhage 1 (8%)
Renal, Pigmentation 1 (7%) 1 (8%)
Lymph Node, Mandibular (49) (51) (52) (54)
Hemorrhage 1 (2%) 1 (2%)
Hyperplasia, Lymphoid 2 (4%) 1 (2%)
Lymph Node, Mesenteric (55) (55) (55) (56)
Hemorrhage 1 (2%) 1 (2%) 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
Inflammation, Granulomatous 1 (2%)
Lymph Node, Mediastinal (56) (53) (56) (56)
Fibrosis 3 (5%)
Hemorrhage 1 (2%) 5 (9%) 1 (2%) 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
Pigmentation 1 (2%) 1 (2%)
Spleen (56) (55) (56) (56)
Congestion 1 (2%)
Developmental Malformation 2 (4%) 2 (4%) 2 (4%)
Fibrosis 7 (13%) 13 (24%) 18 (32%) 15 (27%)
Hemorrhage 1 (2%)
Hyperplasia, Re Cell 4 (7%) 1 (2%)
Necrosis 1 (2%) 2 (4%)
Thymus (55) (52) (54) (56)
Hemorrhage 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (55) (55) (56) (56)
Galactocele 1 (2%) 2 (4%) 3 (5%)
Hemorrhage 1 (2%)
Inflammation, Chronic 1 (2%)
Epithelium, Hyperplasia 1 (2%) 3 (5%) 1 (2%)
Skin (56) (55) (56) (56)
Acanthosis 2 (4%) 2 (4%) 3 (5%)
Cyst 1 (2%)
Cyst Epithelial Inclusion 2 (4%) 1 (2%) 1 (2%)
Hyperkeratosis 1 (2%) 2 (4%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 05133-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:11:11
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - CONT
Inflammation, Chronic 1 (2%)
Inflammation, Granulomatous 2 (4%) 1 (2%) 3 (5%)
Inflammation, Suppurative 1 (2%)
Ulcer 4 (7%) 1 (2%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemorrhage 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (56) (55) (56) (56)
Developmental Malformation 1 (2%)
Fibrosis 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (56) (55) (56) (56)
Demyelination 1 (2%)
Gliosis 1 (2%)
Hemorrhage 3 (5%) 5 (9%) 6 (11%) 4 (7%)
Hydrocephalus 7 (13%) 7 (13%) 7 (13%) 2 (4%)
Necrosis 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (56) (54) (56) (56)
Foreign Body 4 (7%) 4 (7%) 5 (9%) 9 (16%)
Hyperplasia 1 (2%) 4 (7%) 1 (2%) 4 (7%)
Inflammation, Suppurative 5 (9%) 3 (6%) 4 (7%) 8 (14%)
Metaplasia, Squamous 1 (2%) 2 (4%) 1 (2%)
Mineralization 1 (2%) 1 (2%)
Lung (56) (55) (56) (56)
Embolus 1 (2%)
Hemorrhage 24 (43%) 37 (67%) 34 (61%) 35 (63%)
Infarct 1 (2%)
Infiltration Cellular, Histiocyte 10 (18%) 16 (29%) 14 (25%) 11 (20%)
Metaplasia, Osseous 1 (2%)
Thrombosis 1 (2%)
Alveolar Epithelium, Hyperplasia 3 (5%) 7 (13%) 4 (7%) 10 (18%)
Alveolus, Fibrosis 2 (4%) 1 (2%) 7 (13%)
Alveolus, Inflammation, Chronic 4 (7%) 2 (4%)
Alveolus, Mineralization 1 (2%) 1 (2%)
Alveolus, Pigmentation 1 (2%) 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
Pleura, Fibrosis 1 (2%) 1 (2%)
Nose (56) (55) (56) (56)
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
NTP Experiment-Test: 05133-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:11:11
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Foreign Body 10 (18%) 9 (16%) 7 (13%) 7 (13%)
Hemorrhage 6 (11%) 3 (5%) 2 (4%) 5 (9%)
Inflammation, Chronic 2 (4%) 2 (4%) 3 (5%) 2 (4%)
Inflammation, Suppurative 4 (7%) 4 (7%) 6 (11%) 10 (18%)
Goblet Cell, Respiratory Epithelium,
Hypertrophy 9 (16%) 4 (7%) 8 (14%) 3 (5%)
Nasolacrimal Duct, Inflammation 1 (2%)
Nasopharyngeal Duct, Hyperplasia 1 (2%)
Olfactory Epithelium, Metaplasia 1 (2%)
Respiratory Epithelium, Hyperplasia 5 (9%) 5 (9%) 6 (11%) 8 (14%)
Trachea (56) (55) (56) (56)
Peritracheal Tissue, Fibrosis 1 (2%)
Peritracheal Tissue, Inflammation, Chronic
Active 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (1) (2) (2)
Cataract 1 (100%) 2 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (56) (55) (56) (56)
Nephropathy, Chronic 52 (93%) 55 (100%) 55 (98%) 56 (100%)
Thrombosis 1 (2%)
Cortex, Necrosis 1 (2%) 1 (2%) 3 (5%)
Pelvis, Dilatation 1 (2%) 1 (2%)
Pelvis, Transitional Epithelium, Hyperplasia 3 (5%) 3 (5%) 1 (2%) 1 (2%)
Renal Tubule, Hyperplasia 1 (2%) 1 (2%)
Renal Tubule, Mineralization 1 (2%) 1 (2%)
Urinary Bladder (56) (55) (56) (56)
Hemorrhage 2 (4%) 1 (2%)
Inflammation, Suppurative 1 (2%)
Metaplasia, Squamous 1 (2%)
Mineralization 1 (2%)
Ulcer 1 (2%)
Transitional Epithelium, Hyperplasia 2 (4%) 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------